Failure to innovate driving drugmakers down; industry consolidation accelerating towards collapse

At the 2011 Lux Executive Summit, we talked about what comes after “Open Innovation” and how opportunities can result from collaborating with groups that are indifferent or even hostile to your own organization. Big pharma seems to be taking the idea very seriously, if GlaxoSmithKline (GSK) CEO Andr...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email Thank you!

Related Research

New insights about human immune response to COVID-19 have implications for vaccine design against new variants

News Commentary | May 07, 2021

Multiple new and emerging COVID‑19 variants with higher transmission rates have thrown into question the continued efficacy of existing vaccines across these newer strains. Previous research has focused on the receptor‑binding domain (RBD) given its importance in attaching to and infecting human ... To read more, click here.

Sanofi acquires mRNA therapeutics company Translate Bio for a whopping $3.2 billion

News Commentary | August 04, 2021

Sanofi has faced setbacks in trying to develop vaccines against COVID‑19, with clinical trials demonstrating a failure in triggering an immune response. This buyout of Translate Bio suggests a shift in strategy to push forward a full pipeline of mRNA therapies. This move will cause other pharma ... Not part of subscription

Is it time for AI for drug discovery as a service?

Case Study | October 25, 2021

Despite the value of AI to the pharmaceutical industry in the drug discovery space, significant barriers to its adoption remain. One of the major barriers lies in developing the relevant AI capabilities to tackle questions around novel target identification, lead identification and optimization, ... Not part of subscription